[Severe hypercalcemia of unusual cause, looking for the culprit: Case report and review of the literature].

Service d'endocrinologie et diabétologie, CHU Grenoble-Alpes, 38700 La Tronche, France; Service de néphrologie, centre hospitalier métropole Savoie, 73000 Chambéry, France. Electronic address: mjalbert@chu-grenoble.fr. Service de néphrologie, centre hospitalier métropole Savoie, 73000 Chambéry, France. Laboratoire de médecine nucléaire, centre hospitalier métropole Savoie, 73000 Chambéry, France. Pharmacie, centre hospitalier métropole Savoie, 73000 Chambéry, France.

Nephrologie & therapeutique. 2018;(4):231-236
Full text from:

Abstract

INTRODUCTION Hypercalcemia is not a rare event and can lead to severe consequences. Its main etiologies are primary hyperparathyroidism and neoplasic conditions. The iatrogenic etiology by vitamin D intoxication is more rarely found. CASE PRESENTATION A 76-year-old finish woman comes to the emergency room for chest pain. Her medical history is impossible to specify due to the language barrier and initial confusion. She has severe hypercalcaemia (4.14mmol/L), renal insufficiency, cardiac arrhythmia later complicated by an ischemic cardiac episode. Clinic and biologic examinations initially guided the research towards a hematological and neoplasic pathology. The iatrogenic etiology will be permitted by the contribution of details on its medical history and treatment learnt secondly. She was treated for post-surgical hypoparathyroidism by dihydrotachysterol, a vitamin D derivative. The cessation of substitution, treatment with hydration and biphosphonates allowed the rapid correction of hypercalcemia. DISCUSSION Dihydrotachysterol intoxication is a rare etiology of hypercalcemia. Because of the longer half-life of this molecule, the risk of hypercalcemia seems to be greater than with other vitamin D derivatives. This molecule, withdrawn from the French market in 1982, is not detected by the dosage of 25 and 1.25 OH vitamin D. CONCLUSION We report an original case of intoxication by dihydrotachysterol. The risk of hypercalcemia encountered with this molecule must be known. The close medical follow-up recommended in case of hypoparathyroidism seems to be particularly necessary in case of supplementation by this molecule.

Methodological quality

Publication Type : Case Reports ; Review

Metadata

MeSH terms : Dihydrotachysterol ; Vitamin D